JW Pharmaceutical Corporation

A001060

KR7001060003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-26 pm EDT			5-day change	1st Jan Change
28,950 ^KRW	-0.34%		-2.85%	-18.57%

Mar. 14	JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 22	CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	MT

Tranche Update on JW Pharmaceutical Corporation's Equity Buyback Plan announced on September 12, 2018.

November 30, 2018 at 01:15 am EST

From September 12, 2018 to November 29, 2018, the company has repurchased 221,240 shares, representing 1.12% for KRW 9,079.61 million. With this, the company has completed the repurchase of 221,240 shares, representing 1.12% for KRW 9,079.61 million under the buyback announced on September 12, 2018.

Latest news about JW Pharmaceutical Corporation

JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	Jan. 22	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
South Korean Shares Touch Seven-Month Low on Concerns over US Fed Rate Hikes	23-10-20	MT
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates	23-10-20	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Celleron Therapeutics Ltd acquired Argonaut Therapeutics Limited from JW Pharmaceutical Corporation and Oxford Science Enterprises.	23-01-04	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
JW Pharmaceutical to Raise $3 Million via Share Sale	22-10-20	MT
JW Pharmaceutical Corporation announced that it expects to receive KRW 9.999993492 billion in funding	22-10-19	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
JW Pharmaceutical Corporation announced that it has received KRW 398.470716 million in funding	21-12-12	CI
JW Pharmaceutical Corporation announced that it expects to receive KRW 398.470716 million in funding	21-12-02	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
JW Pharmaceutical Corporation(KOSE:A001060) dropped from KOSPI 200 Index	21-09-14	CI
JW Pharmaceutical Corporation announced that it has received KRW 300 million in funding	21-06-17	CI
Market Chatter: JW Pharmaceutical Gets German Health Body's Permit for Phase 2a Study of Oral Atopic Dermatitis Drug	21-04-21	MT
Market Chatter: South Korean Drugmakers Queue Up for Clearance of COVID-19 Treatments in January	21-01-04	MT
JW Pharmaceutical Corporation completed the acquisition of 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd.	19-12-30	CI
JW Pharmaceutical Corporation agreed to acquire the remaining 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd..	19-11-26	CI
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China	19-09-27	CI
JW Pharmaceutical Corporation acquired Euvipharm Pharmaceutical Joint-Stock Company.	19-09-03	CI

Chart JW Pharmaceutical Corporation

Duration

Period

More charts

Company Profile

JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for JW Pharmaceutical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28,950 KRW

Average target price

41,667 KRW

Spread / Average Target

+43.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JW PHARMACEUTICAL CORPORATION	-18.57%	496M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.74%	594B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.44%	205B
ROCHE HOLDING AG	-5.97%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

Pharmaceuticals

Tranche Update on JW Pharmaceutical Corporation's Equity Buyback Plan announced on September 12, 2018.

Latest news about JW Pharmaceutical Corporation

Chart JW Pharmaceutical Corporation

Company Profile

Income Statement Evolution

Ratings for JW Pharmaceutical Corporation

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals